

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Brii Biosciences Limited
騰盛博藥生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2137)

**(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR;
(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
AND
(3) CHANGE IN COMPOSITION OF AUDIT AND RISK COMMITTEE,
NOMINATION COMMITTEE AND STRATEGY COMMITTEE**

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that Dr. Axel Bouchon tendered his resignation letter to resign as a non-executive Director with effect from September 30, 2022.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Dr. Taiyin Yang has been appointed as an independent non-executive Director with effect from September 1, 2022.

CHANGE IN COMPOSITION OF AUDIT AND RISK COMMITTEE, NOMINATION COMMITTEE AND STRATEGY COMMITTEE

The Board hereby announces the following change in composition of the Board committees:

- (i) Following the resignation of Dr. Axel Bouchon, he has also ceased to be a member of the Strategy Committee with effect from September 30, 2022;
- (ii) Following the appointment of Dr. Taiyin Yang, she has also been appointed as a co-chairlady of the Audit and Risk Committee, alongside with Ms. Grace Hui Tang, a co-chairlady of the Audit and Risk Committee, with effect from September 1, 2022;
- (iii) Mr. Gregg Huber Alton has been appointed as the chairman of the Nomination Committee with effect from September 1, 2022;
- (iv) Dr. Zhi Hong has ceased to be the chairman of the Nomination Committee and will remain as a member of the Nomination Committee with effect from September 1, 2022;

- (v) Dr. Martin J Murphy Jr has ceased to be a member of the Audit and Risk Committee with effect from September 1, 2022; and
- (vi) Mr. Yiu Wa Alec Tsui has ceased to be a member of the Nomination Committee with effect from September 1, 2022.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Brie Biosciences Limited (the “**Company**”) hereby announces that Dr. Axel Bouchon (“**Dr. Bouchon**”) tendered his resignation letter to resign as a non-executive Director with effect from September 30, 2022 in order to devote more time to his other commitments, including as the chief executive officer of a start-up company focusing on anti-depression. Following the resignation of Dr. Bouchon as a non-executive Director, he has also ceased to be a member of the strategy committee of the Board (the “**Strategy Committee**”) with effect from September 30, 2022.

Dr. Bouchon has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Dr. Bouchon for his valuable contribution to the Company during his tenure of service.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Dr. Taiyin Yang (“**Dr. Yang**”) has been appointed as an independent non-executive Director with effect from September 1, 2022. Following the appointment of Dr. Yang as an independent non-executive Director, she has also been appointed as a co-chairlady of the audit and risk committee of the Board (formerly known as the audit committee of the Board) (the “**Audit and Risk Committee**”), alongside with Ms. Grace Hui Tang, a co-chairlady of the Audit and Risk Committee, with effect from September 1, 2022.

The biographical details of Dr. Yang are set out below:

Dr. Yang, aged 69, has been appointed as an independent non-executive Director with such appointment to take effect from September 1, 2022. She has more than four decades of experience in developing and manufacturing medicines in several therapeutic categories.

Dr. Yang has been serving as a director of the board and a member of the audit committee of Kodiak Sciences Inc., a biopharmaceutical company listed on NASDAQ Stock Exchange in the United States (stock code: KOD), since December 2019. She has been serving as a director of the board and a member of the nominating and governance committee of Kronos Bio, Inc., a biopharmaceutical company listed on NASDAQ Stock Exchange in the United States (stock code: KRON), since March 2021 and a member of its audit committee since August 2022, respectively. She has been serving as a member of the expert scientific advisory committee of Medicines for Malaria Venture, a non-profit research and development organization, since March 2020. She has been serving as a member of the scientific advisory board of Sionna Therapeutics since August 2022.

Dr. Yang held several positions in Gilead Sciences, Inc. (“**Gilead**”), a biopharmaceutical company listed on NASDAQ Stock Exchange in the United States (stock code: GILD), from March 1993 to July 2022, including director of analytical chemistry and senior vice president of pharmaceutical development and manufacturing. Her last position at Gilead was executive vice president of pharmaceutical development and manufacturing, during which she was responsible for development and manufacturing for Gilead’s small molecules, biologics and antibody-drug conjugates in development programs and commercial products. She directed operations of process, device and formulation development, manufacturing, packaging, analytical operations, laboratory information systems and data science, quality assurance, regulatory affairs, chemistry, manufacturing and controls processes program management, product distribution, supply chain management and site operations including production, quality control, technical services, facility, engineering and environment, health and safety. Under her leadership, Gilead developed the world’s first human immunodeficiency virus single tablet regimen in 2006 and advanced numerous compounds from early-stage development to market, reaching millions of people around the world. During her tenure at Gilead, she also served as the executive sponsor for Gilead Asian Interest Network, an employee resource group established in April 2018, to promote, support and encourage inclusion and diversity. Before that, she held various positions in Syntex Corporation from January 1980 to March 1993, including staff researcher, department head of methods development and director of chemical analysis, supporting drug development.

Dr. Yang has been admitted as a fellow of the American Institute for Medical and Biological Engineering in March 2021 and was elected as a member of the National Academy of Engineering in February 2022.

Dr. Yang obtained a Bachelor of Science Degree in Chemistry from the National Taiwan University in Taiwan, the People’s Republic of China in June 1974, and a Ph.D. in Organic Chemistry from University of Southern California in the United States in January 1980.

Dr. Yang has entered into an appointment letter with the Company for an initial term of three years commencing from September 1, 2022, which may be terminated by not less than one month’s notice in writing in advance served by either Dr. Yang or the Company. Dr. Yang will hold office until the next annual general meeting of the Company at which she will be eligible for re-election. Thereafter, Dr. Yang will be subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Pursuant to the appointment letter, Dr. Yang will receive 109,000 restricted share units per annum for her services as an independent non-executive Director and a committee member, which is determined by the Board having regard to the recommendation of the remuneration committee of the Board and with reference to her experience and relevant duties and responsibilities within the Company.

As at the date of this announcement, Dr. Yang does not have any interest in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Dr. Yang (i) does not hold any other positions with the Company or any of its subsidiaries; (ii) does not hold, and has not held in the last three years, any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (iii) has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed above, there is no other information in relation to the appointment of Dr. Yang which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange, nor are there other matters in relation to the appointment of Dr. Yang that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its warm welcome to Dr. Yang for joining the Company.

CHANGE IN COMPOSITION OF AUDIT AND RISK COMMITTEE, NOMINATION COMMITTEE AND STRATEGY COMMITTEE

The Board hereby announces the following change in composition of the Board committees:

- (i) Following the resignation of Dr. Bouchon as a non-executive Director, he has also ceased to be a member of the Strategy Committee with effect from September 30, 2022;
- (ii) Following the appointment of Dr. Yang as an independent non-executive Director, she has also been appointed as a co-chairlady of the Audit and Risk Committee, alongside with Ms. Grace Hui Tang, a co-chairlady of the Audit and Risk Committee, with effect from September 1, 2022;
- (iii) Mr. Gregg Huber Alton, an independent non-executive Director, has been appointed as the chairman of the nomination committee of the Board (the “**Nomination Committee**”) with effect from September 1, 2022;
- (iv) Dr. Zhi Hong, an executive Director and the chairman of the Board, has ceased to be the chairman of the Nomination Committee and will remain as a member of the Nomination Committee with effect from September 1, 2022;
- (v) Dr. Martin J Murphy Jr, an independent non-executive Director, has ceased to be a member of the Audit and Risk Committee with effect from September 1, 2022; and
- (vi) Mr. Yiu Wa Alec Tsui, an independent non-executive Director, has ceased to be a member of the Nomination Committee with effect from September 1, 2022.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, September 1, 2022

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive Directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive Directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive Directors.